Clinical Trial Search

Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants

Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants

Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…

Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale

Primary: Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment — 495; 400; 67; 46 Number of attacks

Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03

Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days

Primary: Percentage of Participants Admitted to the Hospital for Headache — 6.0; 2.1 percentage of participants

Primary: Number of Subjects With Daily Headache Who Have Continuous Headache — 18; 27 participants

Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants

Primary: Reduction in Headache Intensity — 6; 4; 1; 3 Participants

Primary: 75% Migraine Responder Rate — 38; 37; 33; 33 Participants — p=0.0330

Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) — 91 Participants

Primary: Total Number of Responders — 17 Participants

Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days

Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001

Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027

Primary: Incidence Rate of Dysphagia — 0.4 events per 1,000 person-months

Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days

Primary: Change From Baseline in the Frequency of Headache Days — 22.0; -10.7 headache days

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Change in Migraine Characteristics — 43; 2; 17 Participants

Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001

Primary: Adherence to Acute Migraine Management Strategies: Treat Early — 0; 2 Participants

Primary: Change From Baseline in Monthly Migraine Days — -4.18; -6.64; -6.63 migraine days / month — p=<0.001

Primary: Total Sleep Time — 5.4; 5.5; 6.3; 6.1 hours — p=0.33

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7. — -7.61; -6.67; -9.72; -5.22 days

Primary: Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week…

Primary: Change From Baseline in Number of Migraine Days Per Four Weeks During the Three Months Post Treatment Investigation Duration — -1.5; -1.3 Migraine days/four weeks…